Follow our Journeys
Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.
Tune Therapeutics Unveils Breakthrough Data Showing Stable and Durable Epigenetic Regulation in Non-Human Primates
Tune Therapeutics is a Duke University start-up developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Duke Capital Partners Leads Investment in Reselute
Reselute, founded around Duke technology by a Duke professor and graduates, is developing solutions to orthopedic infections
Read More about Duke Capital Partners Leads Investment in Reselute
Investor Spotlight: Ruby Grewal, BSE’88, MBA’93
With dual Duke degrees and deep experience in healthcare and finance, Ruby Grewal brings a unique investor lens to Duke Capital Partners
Read More about Investor Spotlight: Ruby Grewal, BSE’88, MBA’93
Ten63 Therapeutics Raises $15.9 Million in Oversubscribed Series A Financing to Drug the Undruggables by Combining the Power of AI and Physics-based Models
Duke Capital Partners portfolio company Ten63 was co-founded by Professor Bruce Donald (Computer Science, Trinity) and students
Levitate Raises $14M to Help Businesses Keep in Touch More Authentically, Powered by AI
Levitate's oversubscribed $14M funding round will fuel growth of the company's Happiness Platform for relationship-based businesses
Duke Capital Partners is hiring
Duke Capital Partners is hiring a Senior Associate Director, an Assistant Director, and a Senior Program Coordinator to join our fast-moving team.